Naveen Pemmaraju: TRANSFORM-1 results randomized Phase 3 clinical trial at EHA24

Naveen Pemmaraju shared on X:

“Honored to present at EHA24 today the TRANSFORM-1 results from a randomized Phase 3 clinical trial. Ruxo + Navitoclax frontline vs Ruxo + placebo in a cohort of 252 patients, with a median follow-up of 20.3 months. SVR35w24 observed at 63.2% for Navitoclax + Ruxo vs 31.5% for Ruxo + placebo to the primary endpoint met.”

Source: Naveen Pemmaraju/X

Naveen Pemmaraju is a Professor and Director of the BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of the MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN, and AML.

He was named MDACC’s, Department of Leukemia, Inaugural Director of the BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.